Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (November 2024)
44 slides from Astrazeneca's investor day presentation, Nov 15, 2024
Slide 1: Health Equity at AstraZeneca
Health Equity at AstraZeneca Event for investors and analysts 15 November 2024 November 2024
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Agenda
Agenda I. Sustainability at AstraZeneca Pam Cheng Dave Fredrickson II. Our Health Equity Journey and Marc Dunoyer III. Our Health Equity Strategy IV. Equity in Action Health Equity V. Q&A Panel Leadership Team 3
Slide 4: Sustainability at AstraZeneca
Sustainability at AstraZeneca Pam Cheng E X E C U T I V E V I C E P R E S I D E N T, G L O B A L O P E R AT I O N S , I N F O R M AT I O N T E C H N O L O G Y A N D C H I E F S U S TA I N A B I L I T Y O F F I C E R 44
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Working on “today, tomorrow and the day after” Illustrative only, not to scale Beyond 2030: Disruptive categories with New medicines in the potential to transform development $80bn healthcare landscape • Smart chemotherapy (ADCs) Ambiti
Slide 6: Sustainability is core part of achieving our ambitions
Sustainability at AZN Sustainability is core part of achieving our ambitions Growth & therapy Science & innovation Global footprint area leadership • Invest in new • Transform patient • Broad-based network technologies and outcomes through • Differentiated Emerging modalities novel medicines Markets
Slide 7: Industry-leading efforts in Sustainability
Sustainability at AZN Industry-leading efforts in Sustainability Our three interconnected priorities underpinned by nine focus areas Progress on our leadership in Equitable access sustainability includes: 15 Affordability and pricing Ambition Zero Carbon Health system Product public and private sect
Slide 8: Driving bold decarbonisation through Ambition Zero Carbon
Sustainability at AZN Driving bold decarbonisation through Ambition Zero Carbon Scope 1 & 2 Scope 3 Total Revenue vs. Scope 1 & 2 emissions TARGETS: TARGETS: 68% Reduce Scope 1 & 2 98% $50,000 700,000 Of suppliers with emissions vs. 2015 by 2026 65% science-based 20251 Scope 1 & 2 Emissions (tCO2e)
Slide 9: Building more sustainable and resilient healthcare systems across the world
Sustainability at AZN Building more sustainable and resilient healthcare systems across the world Partnership for Health System Sustainability and Resilience (PHSSR) Key ongoing initiatives Co-founded by: Orphan Drug Protections Active in >30 countries Partnering to drive focused interventions, poli
Slide 10: Acting now to secure a sustainable future for all
Sustainability at AZN Acting now to secure a sustainable future for all Climate action Resilience Health equity z z z The climate crisis is worsening Health systems are unable to Health disparities are widening the burden of disease cope with rising demands within and between countries 10
Slide 11: Health Equity at AstraZeneca
Health Equity at AstraZeneca Dave Fredrickson E X E C U T I V E V I C E P R E S I D E N T, ONCOLOGY BUSINESS 11
Slide 12: Our journey to date: A foundation of successful philanthropic programmes
Journey Strategy Equity in Action Our journey to date: A foundation of successful philanthropic programmes 2010 – TODAY 66.4m people reached through philanthropic programs1 surpassing target of 50m by 2025 Young Health Healthy Lung HHA CKD Programme Programme Expansion 2010 2022 2024 2016 2017 >127,
Slide 13: Our journey to date: Expanding access via strategic adjacencies across our therapeutic areas
Journey Strategy Equity in Action Our journey to date: Expanding access via strategic adjacencies across our therapeutic areas 2010 – TODAY The Lung Ambition[]to eliminate lung Ambition cancer as a cause of death Alliance Young Health Healthy Lung Lung Ambition US ACT on HHA CKD Programme Programme
Slide 14: Care gaps exist at every step of the patient journey
Journey Strategy Equity in Action Care gaps exist at every step of the patient journey Treatment Early Precision Guideline- adherence detection diagnosis based care and disease monitoring 14
Slide 15: Determinants of health outcomes amplify these care gaps globally
Journey Strategy Equity in Action Determinants of health outcomes amplify these care gaps globally Determinants of health outcomes Treatment Early Precision Guideline- adherence Behavioural detection diagnosis based care and disease monitoring Genetic Social Environmental 15
Slide 16: The journey to our Health Equity strategy
Journey Strategy Equity in Action Broadening “Access to Healthcare” to “Health Equity” at AstraZeneca The journey to our Health Equity strategy Evaluate Engage Action current and future key stakeholders high-impact health equity initiatives to enable change opportunities >170 Conducted interviews Em
Slide 17: Our vision is to drive health equity across all healthcare systems and income segments
Journey Strategy Equity in Action Our vision is to drive health equity across all healthcare systems and income segments Equity focus across income segments High income Our vision: Variation in population groups within the same country Working to remove barriers to Upper-middle healthcare to give ev
Slide 18: Our Health Equity strategy underpinning our ambition
Journey Strategy Equity in Action Our Health Equity strategy underpinning our ambition Ensure more individuals SCIENCE can equitably benefit from our trials, science Our strategy: and capabilities Improve equitable To achieve holistic health outcomes focus on DELIVERY early detection, precision impa
Slide 19: Leading in discovery diversity with our genomics initiative
Journey Strategy Equity in Action Leading in discovery diversity with our genomics Science initiative Building an extensive ‘omics database since 2017 Our ‘omics diversity progress Next steps SCIENCE 1.4m 100% % of individuals available for patient-centric R&D 90% Driving greater exomes/genomes 80%
Slide 20: Committed to enrolling diverse clinical trial populations to improve equitable access
Journey Strategy Equity in Action Committed to enrolling diverse clinical trial Science populations to improve equitable access Progress to date Next steps SCIENCE CTD Dashboard Establishing Ensure clinical trial populations represent with real-time recruitment tracking for all Phase III collaborati
Slide 21: Growing impact from Young Health Programme
Journey Strategy Equity in Action We remain committed to our philanthropic efforts: Delivery growing impact from Young Health Programme Young Health Programme DELIVERY >15 million young people 16 high income directly reached countries Health awareness and education 18 upper >800,000 middle-income pe
Slide 22: Healthy Heart Africa expanding into CKD
Journey Strategy Equity in Action We remain committed to our philanthropic efforts: Delivery Health Heart Africa expanding into CKD Healthy Heart Africa DELIVERY tackling hypertension and the burden of cardiovascular disease across Africa Health awareness Progress to-date: and education Achieved tar
Slide 23: Partnering along the entire patient journey to close care gaps and improve equitable outcomes
Journey Strategy Equity in Action Partnering along the entire patient journey to close Delivery care gaps and improve equitable outcomes DELIVERY Treatment Awareness and Early Precision Guideline- adherence education detection diagnosis based care and disease monitoring Closing care gaps Affordabili
Slide 24: Partnering along the entire patient journey to close care gaps and improve equitable outcomes
Journey Strategy Equity in Action Partnering along the entire patient journey to close Delivery care gaps and improve equitable outcomes DELIVERY Treatment Awareness and Early Precision Guideline- adherence education detection diagnosis based care and disease monitoring Closing care gaps Only 18% c.
Slide 25: Our four principles to sustainable affordability
Journey Strategy Equity in Action Our four principles to sustainable affordability Delivery Multiple factors influence affordability and accessibility Four principles DELIVERY I. Sustainability of both the healthcare system and our research-led business model Awareness and education II. Value reflec
Slide 26: Affordability and accessibility varies by market
Journey Strategy Equity in Action Affordability and accessibility varies by market Delivery Higher gross national Lower gross national income and accessibility income and accessibility attributes ― Distinct patient segments with differing Market ― High affordability and accessibility levels of acces
Slide 27: Capabilities and engagement
Journey Strategy Equity in Action Capabilities and engagement Engagement Building trust with partners and purpose with employees 11 countries across 5 continents represented CAPABILITIES & AstraZeneca ENGAGEMENT Health Equity Advisory Board established in 2024 Partnerships and stakeholder engagement
Slide 28: Equity in Action across AstraZeneca
Equity in Action across AstraZeneca Dave Fredrickson E X E C U T I V E V I C E P R E S I D E N T, ONCOLOGY BUSINESS Marc Dunoyer CHIEF EXECUTIVE OFFICER, A L E X I O N A N D C H I E F S T R AT E G Y OFFICER, ASTRAZENEC A 28
Slide 29: Lung health is a key priority for AstraZeneca
Journey Strategy Equity in Action Lung health is a key priority for AstraZeneca Unmet need Deep pipeline Our leading medicines and opportunity and ambitions Lung 1/5 of all cancers causing 1.8m deaths >50% of lung cancer patients to be eligible for AstraZeneca cancer in 20201 medicine by 2030 / Addr
Slide 30: Lung health outcomes are influenced by similar barriers across the patient journey
Journey Strategy Equity in Action Lung health outcomes are influenced by similar barriers across the patient journey Determinants of health outcomes Who is impacted? What access barriers do they face? ― Lack of screening and Tobacco consumption Early early diagnosis detection ― Limited healthcare ac
Slide 31: Understanding care gaps with precision analytics to maximise our impact in lung health
Journey Strategy Equity in Action Understanding care gaps with precision analytics to maximise our impact in lung health Identify and execute on actionable Who faces care gaps? drivers of disparities: Areas with low lung cancer incidence and higher mortality rates to inform stage shift strategy in h
Slide 32: Driving early detection of disease through lung screening programs
Journey Strategy Equity in Action Driving early detection of disease through lung screening programs AI-powered UK lung cancer diagnostic partnership screening programme driving more lung cancer diagnoses leveraging chest x-rays globally in deprived groups2 ― Drove initial awareness campaign ― 17% i
Slide 33: Breathlessness is a common symptom across diseases; delayed diagnosis associated with worse outcomes
Journey Strategy Equity in Action Breathlessness is a common symptom across diseases; delayed diagnosis associated with worse outcomes Delayed diagnosis associated with worse Cardiac clinical outcomes Heart failure 38% of patients received More severe first HF diagnosis HF at diagnosis3 in an acute
Slide 34: Accelerating diagnosis of heart failure and COPD through community-based screening
Journey Strategy Equity in Action Accelerating diagnosis of heart failure and COPD through community-based screening Leveraging AI to accelerate Innovative Community detection of Heart Failure outreach through sports club ― Validated AI-assisted ultrasound ― Heart and lung screening hub in testing o
Slide 35: Improving cardiac amyloidosis diagnosis through innovative AI partnerships
Journey Strategy Equity in Action Improving cardiac amyloidosis diagnosis through innovative AI partnerships Amyloidosis Enhancing detection of Accelerating amyloidosis disease patient journey amyloidosis signatures detection to drive earlier intervention via AI software and improve patient outcomes
Slide 36: Amyloidosis is a strategic priority across CVRM and Rare Disease
Journey Strategy Equity in Action Amyloidosis is a strategic priority across CVRM and Rare Disease A portfolio to address the two most prevalent cardiac amyloidosis Transthyretin (ATTR) amyloidosis Light-chain (AL) amyloidosis ADCs and Cell therapy Wainua RCs Complimentary mechanisms Silencer blocks
Slide 37: Being born with a rare disease is inherently inequitable
Journey Strategy Equity in Action Being born with a rare disease is inherently inequitable z 1 in 10 10,000 80% zknown rare diseases people live with a of rare diseases >90% do not have an rare disease1 are genetic approved treatment2,3 z 5+ years z 80% 6-10x z higher and >7 specialists to economic
Slide 38: Patients with rare disease face multiple inequities across the diagnosis and treatment pathway
Journey Strategy Equity in Action Patients with rare disease face multiple inequities across the diagnosis and treatment pathway Sparse or Limited knowledge Limited access limited data and understanding z Poor access Disproportionate Long and complex and quality of impact on health diagnostic pathwa
Slide 39: Newborn screening, one of the most successful public health programmes
Journey Strategy Equity in Action Newborn screening, one of the most successful public health programmes but only covers a small fraction of diseases today Current newborn Challenges screening progress Next steps for next-generation 40m newborns ― Screening covers too few diseases: sequencing for: s
Slide 40: Establishing newborn screening as standard-of-care as part of BeginNGS
Journey Strategy Equity in Action Establishing newborn screening as standard-of-care as part of ‘BeginNGS’ genome sequencing consortium 80% ofarerare diseases genetic 2 Progress to date: Today >700 BeginNGS ambition >600 aligned with our genomic medicine strategy Consortium focused on Number of gene
Slide 41: Driving health equity while delivering shareholder value
Driving health equity while delivering shareholder value 2030 Ambition Health Equity Ambition Our vision: To deliver $80bn in Total Revenue by 2030, with sustained growth 2030+ working to remove barriers to healthcare to give everyone the chance to be as healthy as possible z z ― Mid-30s% Core opera
Slide 42: Q&A Session
Q&A Session with Key Health Equity Leaders Pam Cheng EXECUTIVE VICE PRESIDENT, GLOBAL Stefan Weber OPERATIONS, INFORMATION VICE PRESIDENT, POLICY, PATIENT TECHNOLOGY AND CHIEF ADVOCACY AND HEALTH EQUITY SUSTAINABILITY OFFICER Dave Fredrickson Elena Tricca EXECUTIVE VICE PRESIDENT, VICE PRESIDENT, GL
Slide 43: Sustainability Governance at AstraZeneca
Sustainability Governance at AstraZeneca Board of Directors – Delegated Committees Board Audit Committee Sustainability Committee Remuneration Committee Philip Broadley Nazneen Rahman Sheri McCoy Senior Independent Non-Executive Director of the Board, Non-Executive Director of the Board, Non-Executi
Slide 44: Use of AstraZeneca slides from conference calls and webcasts
Use of AstraZeneca slides from conference calls and webcasts The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to th